{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-007951","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.332688+00:00","generated_at":"2026-06-25T21:54:08.084641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immuneering Q1 net loss $12.9M; reiterates FY2022 opex $55-60M; IMM-1-104 IND on track for Q3 2022","bullets":["Net loss $12.9M ($0.49/share) vs $6.2M ($1.26/share) in Q1 2021; R&D $9.1M, G&A $4.0M.","Cash $137.8M as of March 31, 2022; cash runway into Q3 2024.","IMM-1-104 IND filing expected Q3 2022; first patient enrollment Phase 1 expected Q4 2022.","IMM-6-415 IND filing expected 2023.","FY2022 GAAP opex guidance $55-60M including non-cash stock-based comp."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-007951","json":"https://secwatch.observer/filing/0001558370-22-007951.json","markdown":"https://secwatch.observer/filing/0001558370-22-007951.md","text":"https://secwatch.observer/filing/0001558370-22-007951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000155837022007951/0001558370-22-007951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000155837022007951/imrx-20220510x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:54:08.084641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}